John LaMattina

Latest Headlines

Latest Headlines

PureTech bumps its early life science funds up to $107M

Not quite a venture firm, research institute or startup, PureTech is a bit of all three. The mission of the early stage research company just got a little bit easier--it bumped up its recent fundraising to $107 million from the $57 million it had raised as of October.

In confidence survey, VCs sound lukewarm about biotech

In a confidence survey from Deloitte and the National Venture Capital Association, respondents lacked faith in the future of the biopharma industry, and the low confidence bodes poorly for an industry already suffering from dwindling VC dollars.

UPDATED: New cloud hovers over class of 'good cholesterol' drugs

Fresh doubts have cropped up for raising "good cholesterol" to combat heart attack risk, after a new study showed that patients genetically programmed to have higher levels of HDL cholesterol didn't appear to be more protected from heart disease than those with low levels.

Ex-Pfizer R&D chief questions calls for wholesale pharma outsourcing

Big Pharma companies have been farming out more of their R&D in recent years to keep spending in check, yet the experts have clashed over how much outsourcing can be done without threatening the

LaMattina gives insider's view of R&D 'upheaval' at Pfizer

John LaMattina has provided some new insights from his past days inside the belly of the Pfizer beast, this time in a candid interview with Pharmalot's Ed Silverman. And the drug giant's former

Ex-Pfizer R&D chief: Big Pharma mergers, cutbacks badly damaged drug research

John LaMattina doesn't have much to say in favor of Pfizer's business strategy over recent years. In a piece for Nature, the former Pfizer ($PFE) R&D chief marshals his arguments against the Big

Ex-Pfizer R&D chief LaMattina criticizes short-term pharma strategy

John LaMattina has some advice for Pfizer ($PFE), where he worked for 30 years before retiring as the head of research. Once the pharma giant finishes chopping the R&D budget to around $6.5

Will new drug partnerships force a fresh take on costs?

There's nothing new about partnering in drug development. It's been going on for years. But the mantra on collaboration is becoming an article of faith these days, as a new analysis piece from

Former Pfizer R&D exec jumps into VC game

John LaMattina, Pfizer's former R&D chief, has made the leap into the venture field, joining PureTech Ventures as a senior partner. After putting in 30 years at the drug giant, LaMattina retired

C&L: Una Ryan leaves Avant

Avant Immunotherapeutics today announced the departure of Una Ryan, Ph.D, President and CEO, effective immediately. Watson Pharmaceuticals announced that co-founder and Chairman Allen Chao has